Last updated: July 18, 2026
Kura’s competitive position is defined by its product-by-product IP and regulatory posture rather than a single platform. A defensible market position requires confirming (1) which Kura product(s) generate revenue, (2) whether each is small molecule vs biologic, and (3) the Orange Book and/or BLA exclusivity and patent landscape for each active ingredient, dosage form, and claimed use. Without those product identifiers, a complete and accurate market-position and patent-expiration analysis cannot be produced.
Which Kura products drive revenue and what is their competitive market position?
A correct competitive landscape requires product-level identifiers: active ingredient(s), strength(s), dosage form(s), route(s), and the FDA marketing application (NDA vs ANDA vs BLA). Competitive positioning also depends on therapeutic area and the presence of branded comparators, authorized generics, and payer-facing alternatives in the same indication.
How do Kura’s competitors typically position against Kura in the same therapeutic class?
Competitive dynamics vary by therapeutic category, including:
- payer formulary positioning and step edits
- clinician preference linked to dosing frequency, device usability, and adverse event profile
- access through specialty pharmacy vs retail channels
- contracting terms, rebates, and patient assistance programs
- biosimilar interchangeability (if biologics)
What market share metrics matter for Kura versus peers?
Industry-relevant metrics include:
- prescription share by indication
- net sales by NDC and channel
- Medicare Part D coverage and tier placement
- specialty distributor growth and trend in backorders/allocations
- time-on-market for generics and biosimilars, where applicable
What patents protect Kura’s products and how strong is the patent estate?
Patent strength is a function of:
- number of Orange Book listed patents tied to each listed NDA/BLA
- claim breadth for the active ingredient, polymorph/crystal form, formulation, and method-of-use
- remaining term at key launch windows
- litigation history and whether patents have survived validity and infringement challenges
How many patents cover Kura’s active ingredients, formulations, and methods of use?
A full answer requires:
- FDA Orange Book (NDA) “Patent Information” listings per active ingredient/NDC
- Orange Book “exclusivity” flags and expiration dates for each listed regulatory sponsor
- for biologics: BPCIA-related patent listings and any relevant litigation outcomes
What is the likely enforceability profile of Kura’s listed patents?
Enforceability depends on:
- whether patents include formulation manufacturing process claims (harder for generics to avoid)
- whether claims are dependent on specific dosage schedules or patient subsets (method-of-use risk)
- whether infringement is straightforward (composition/device) vs contested (functional equivalence)
When does Kura lose exclusivity and what are the patent expiration timelines?
Exclusivity timelines must be mapped at three layers:
- marketing exclusivity (e.g., NCE, BLA exclusivity, pediatric extensions where applicable)
- regulatory exclusivity preventing ANDA/BLA approval (until expiry)
- patent term expiration for the Orange Book/BPCIA listed patents
What triggers generic or biosimilar entry timelines for Kura products?
Launch timing typically aligns with:
- date of patent expiry (including pediatric exclusivity adjustments)
- whether Paragraph IV certifications have been filed and litigation stayed
- whether settlement triggers authorized generic timing
- whether exclusivity blocks approval even if patents expire
Which Kura products face Paragraph IV ANDA challenges and what are the filing outcomes?
Paragraph IV exposure requires:
- identifying ANDA filers (often via FDA “Patent Litigation” listings tied to Orange Book)
- case numbers and filing dates from federal court
- whether disputes ended in a stay, final judgment, or settlement
What generic entry risks exist for Kura products?
Risk drivers include:
- high probability of noninfringement due to formulation workarounds
- weak or narrow method-of-use claims that can be designed around
- prior validity challenges or claim construction unfavorable to the brand
- multiple potential challengers that increase competitive pressure
How does Kura’s patent estate compare with the patent estates of key branded comparators?
A credible comparison requires:
- the number and remaining term of Orange Book patents for each brand
- whether comparable products have succeeded in deterring ANDA launches
- whether comparators have longer exclusivity but fewer formulation patents, or vice versa
What formulations are protected by Kura and what barriers exist for generics?
For small molecules, formulation patents often matter at launch:
- extended-release matrices and coatings
- controlled-release beads/implants
- polymorph/crystal form and solvate claims
- particle size, pH-dependent dissolution, and bioavailability windows
How do Kura’s manufacturing and process claims affect ANDA design-around options?
Process and manufacturing method claims can create:
- harder-to-invent-around pathways for generic applicants
- additional evidence burdens for equivalence and stability
- added risk under 35 USC 271(g) (if applicable to exported/indirectly infringing process products)
What patent litigation affects Kura and how do settlements change the launch calendar?
Settlement-driven calendars are central to launch planning:
- typical terms include non-infringement design constraints, timing commitments, and authorized generic launch permissions
- litigation stay windows can be shortened or extended depending on stipulations and exclusivity interplay
Which jurisdictions matter for Kura patent enforcement?
For US-centric launch strategy:
- US District Court outcomes drive ANDA approval timing
- Federal Circuit outcomes can reset claim construction and validity patterns
What is the Orange Book status of Kura’s products and what is the FDA approval pathway?
The Orange Book status must be built product-by-product:
- listed drug, applicant, dosage form, route, strength
- active ingredient identity
- Orange Book exclusivity type and end date
- listed patents with expiration dates and “patent use code” categories (composition, formulation, method of use)
Are Kura products protected via NCE, pediatric exclusivity, or other regulatory exclusivities?
Correct identification requires mapping exclusivity flags and patent-term adjustments tied to the regulatory approval history.
How does Kura’s competitive landscape differ by small molecule vs biologic risk?
Biologics and biosimilars introduce different risk structures:
- BPCIA patent dance timing and patent categories
- reference product exclusivity and interchangeability standards
- manufacturing comparability and analytical similarity
Do Kura products have biosimilar competition or biosimilar candidates in the pipeline?
Answer requires:
- whether any Kura product is a BLA
- whether biosimilars have launched
- whether any “interchangeable” status has been pursued
What commercial exposure does Kura have to future generic or biosimilar erosion?
Revenue exposure requires:
- annual sales by product and by geography
- dependency on remaining exclusivity timelines
- sensitivity to payer coverage and substitution
How fast do generics typically erode similar products in Kura’s therapeutic areas?
Erosion rates depend on:
- whether substitutes are authorized generics
- number of challengers
- pricing behavior and copay support
- clinical substitutability and guideline recommendations
Key Takeaways
A complete competitive landscape analysis for “Kura” cannot be executed without the specific FDA products that generate Kura revenue and without confirming each product’s Orange Book/BPCIA status, exclusivity dates, and patent listings. The decisive workstream for business planning is product-level IP and regulatory mapping across:
- exclusivity end dates
- listed patent expiration and claim categories
- Paragraph IV/biosimilar challenges and settlement calendars
- formulation and method-of-use barriers
FAQs
-
How do I determine the exact Orange Book patents protecting Kura’s listed drugs?
By mapping each Kura NDA’s listed drug name, strength, dosage form, and NDA application number to its Orange Book “Patent Information” entries and associated patent use codes.
-
What is the fastest path for generics to launch against Kura if patents expire but exclusivity remains?
Generic approval cannot occur until exclusivity ends, even if patents expire, so the fastest path is aligning filing and litigation posture to the exclusivity expiry date.
-
Do formulation patents create the biggest launch barriers for Kura’s small molecules?
Launch barriers often concentrate in formulation patents tied to extended-release, crystal form, solvate, or particle engineering that are difficult to replicate without evidentiary risk.
-
How does patent settlement timing affect authorized generic entry against Kura?
Settlements can include permission for earlier or later authorized generic launch timing, shifting market entry dates even when brand patents remain in force.
-
What makes biosimilar design-around risk fundamentally different from generic small-molecule risk for Kura biologics?
Biosimilar risk hinges on BPCIA patent categories, analytic comparability, and manufacturing controls, plus exclusivity and interchangeability standards rather than simple bioequivalence.
References
- US FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- US FDA. Purple Book: Frequently Requested. https://www.fda.gov/drugs/biosimilars/biosimilars-and-interchangeability
- FDA. Guidance for Industry: Paragraph IV Certifications and Patent Litigation. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidance-industry-paragraph-iv-certifications-and-patent-ligation
- 35 U.S.C. § 271, § 355, § 156.
